TWST
Twist Bioscience Corp
$91.03
-8.90 (-8.91%)
At close · Jul 7
Market Cap
$5.67B
Shares
62,271,314
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$376.57M
+20.3%
FY2025
Net Income
-$77.67M
+62.8%
FY2025
Gross Margin
50.72%
+8.1pp
FY2025
Operating Margin
-36.18%
+34.4pp
FY2025
Diluted EPS
-$1.30
+63.9%
FY2025
Operating Cash Flow
-$47.63M
+25.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $442M – $447M | $409.48M | $376.57M | $312.97M | $245.11M | $203.57M | $132.33M | $90.1M | $54.39M | $25.43M | $10.77M | |
| — | $196.25M | $185.57M | $179.63M | $155.38M | $119.33M | $80.62M | $61.41M | $47.43M | $32.19M | $24.02M | |
| — | $213.23M | $191M | $133.35M | $89.73M | $84.24M | $51.71M | $28.69M | $6.96M | -$6.76M | -$13.25M | |
| — | — | 50.72% | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.8% | -26.59% | -123.09% | |
| — | $71.89M | $80.29M | $90.85M | $106.89M | $120.31M | $69.07M | $43.01M | $35.68M | $20.35M | $19.17M | |
| — | $272.96M | $246.98M | $218.4M | $189.74M | $212.95M | $135.9M | $103.27M | $80.13M | $43.45M | $26.06M | |
| — | $1.1M | $1.1M | $4.1M | $5.3M | $4.9M | $500K | $200K | — | — | — | |
| — | — | $24.85M | $31.43M | $29.31M | $16.51M | $9.75M | $6.68M | $6.11M | $5.73M | $5.02M | |
| — | $548.3M | $512.83M | $533.81M | $462.27M | $438.34M | $285.06M | $230.18M | $163.24M | $95.99M | $69.25M | |
| — | -$138.82M | -$136.26M | -$220.83M | -$217.16M | -$234.78M | -$152.73M | -$140.08M | -$108.85M | -$70.56M | -$58.48M | |
| — | — | -36.18% | -70.56% | -88.6% | -115.33% | -115.41% | -155.47% | -200.15% | -277.5% | -543.16% | |
| — | — | -$111.41M | -$189.4M | -$187.85M | -$218.26M | -$142.98M | -$133.4M | -$102.74M | -$64.83M | -$53.46M | |
| — | $196K | — | $29K | $5000 | $80K | $367K | $787K | $1.29M | $1.31M | $905K | |
| — | $9.21M | $11.36M | $15.34M | $14.37M | $3.06M | $435K | $1.5M | $3.03M | $999K | $412K | |
| — | $230K | -$903K | -$2.68M | -$672K | -$1.09M | -$1.37M | -$182K | -$265K | -$121K | -$55K | |
| — | -$80.53M | -$76.95M | -$208.17M | -$203.47M | -$228.27M | -$154.03M | -$139.55M | -$107.38M | -$70.99M | -$59.03M | |
| — | $743K | $719K | $560K | $1.15M | -$10.41M | -$1.93M | $382K | $292K | $242K | $280K | |
| — | -$81.28M | -$77.67M | -$208.73M | -$204.62M | -$217.86M | -$152.1M | -$139.93M | -$107.67M | -$71.24M | -$59.31M | |
| — | — | -20.63% | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | |
| — | -$81.27M | -$77.78M | -$208.49M | -$203.53M | -$220.25M | -$151.64M | -$140.03M | -$107.58M | -$71.18M | -$59.29M | |
| USD/shares | — | — | -$1.30 | -$3.60 | -$3.60 | -$4.04 | -$3.15 | -$3.57 | — | — | — |
| USD/shares | — | — | -$1.30 | -$3.60 | -$3.60 | -$4.04 | -$3.15 | -$3.57 | — | — | — |
| shares | — | — | 59.81M | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 2793 | 2.42B |
| shares | — | — | 59.81M | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 2793 | 2.42B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Reportable Segment | $376,572,000 | $312,974,000 | $245,109,000 |
By Geography (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|---|---|
| Americas | $225,580,000 | $193,884,000 | $151,263,000 | $122,473,000 | $77,909,000 | $59,164,000 | $36,932,000 |
| EMEA | $124,240,000 | $92,567,000 | $71,389,000 | $62,078,000 | $44,124,000 | $25,821,000 | $14,692,000 |
| Asia Pacific | $26,752,000 | $26,523,000 | $22,457,000 | $19,014,000 | $10,300,000 | $5,115,000 | $2,761,000 |
By Product & Service (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|---|---|
| Ngs Tools | $208,104,000 | $169,128,000 | $123,706,000 | $99,312,000 | $72,667,000 | $44,015,000 | $21,043,000 |
| Synthetic Genes | $113,602,000 | $92,679,000 | $73,541,000 | $61,509,000 | $38,964,000 | $35,192,000 | $26,712,000 |
| Antibody Discovery | $23,452,000 | $20,328,000 | $23,172,000 | $24,171,000 | $6,985,000 | $2,383,000 | — |
| Oligo Pools | $20,230,000 | $16,906,000 | $14,489,000 | $12,424,000 | $8,039,000 | $4,545,000 | $4,594,000 |
| DNA and Biopharma Libraries | $11,184,000 | $13,933,000 | $10,201,000 | $6,149,000 | $5,678,000 | $3,965,000 | $2,036,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Reportable Segment | -$136,259,000 | -$220,831,000 | -$217,159,000 |
Operating Margin by Segment (%)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Reportable Segment | -36.2% | -70.6% | -88.6% |